Nanotechnology based drug delivery in cancer treatment: enabling controlled and targeted release of medications
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242641Keywords:
Nanotechnology, Cancer Therapy, Nanoparticles, Targeted Drug Delivery, NanomedicineAbstract
The advent of nanotechnology in drug delivery has revolutionized cancer treatment, offering controlled and targeted release of therapeutic agents. This study investigates the impact and effectiveness of various nanoparticle-grounded drug delivery systems (DDSs) in cancer therapy. A qualitative analysis of secondary literature was conducted to explore the types, targeting mechanisms, and clinical applications of nanoparticles (NPs) in cancer treatment. The study categorized NPs into organic, inorganic, and hybrid types and examined their roles in passive and also active targeting of cancer cells. The findings reveal the significant diversity and efficacy of NPs in enhancing drug delivery efficiency while minimizing systemic toxicity. Notable examples of clinically approved nanotherapeutic formulation medications include Doxil®, Myocet®, and Abraxane®, which have shown improved drug pharmacokinetics and biodistribution. Nanotechnology offers transformative potential in cancer therapy, providing promising avenues for the development of advanced and personalized cancer therapeutics.
References
Ali ES, Sharker SM, Islam MT, Khan IN,. Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives. In seminars in cancer biology 2021;69:52-68.
Kumar V, Rahman M, Gahtori P. Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine. Expert Opinion on Drug Delivery. 2021;18(6):673-94.
Senapati S, Mahanta AK, Kumar S. Controlled drug delivery vehicles for cancer treatment and their performance. Sig Transduct Target Ther. 2018;3:7.
Yao Y, Zhou Y, Liu L, Xu Y, Chen Q. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci. 2020;7:193.
Yu Dang, Jianjun Guan, Nanoparticle-based drug delivery systems for cancer therapy, Sm Mat in Med. 2020;1:10.
Raj S, Khurana S, Choudhari R. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. In seminars in cancer biology. 2021;69:166-77.
Jose J, Kumar R, Harilal S. Magnetic nanoparticles for hyperthermia in cancer treatment: an emerging tool. Environmental Science and Pollution Research. 2020;27:19214-25.
Prasad R, Jain NK, Conde J, Srivastava R. Localized nanotheranostics: recent developments in cancer nanomedicine. Materials Today Advances. 2020;8:100087.
Rodríguez F, Caruana P, De la Fuente N. Nano-based approved pharmaceuticals for cancer treatment: present and future challenges. Biomolecules. 2022;12(6):784.
Parodi A, Kolesova EP, Voronina MV,. Anticancer nanotherapeutics in clinical trials: The work behind clinical translation of nanomedicine. Int J Mole Sci. 2022;23(21):133-68.
Thapa RK, Kim JO. Nanomedicine-based commercial formulations: Current developments and future prospects. J Pharm Inves. 2023;53(1):19-33.
Patel R, Patel M. Current status of machine learning and artificial intelligence in cervical cancer screening and diagnosis: a systematic review. J Med Sci. 2024;6:38-48.
Rasool M, Malik A, Waquar S, Arooj M, Zahid S, Asif M, et al. New challenges in the use of nanomedicine in cancer therapy. Bioengineered. 2022;13(1):759-73.
Gonzalez-Valdivieso J, Girotti A, Schneider J, Arias FJ. Advanced nanomedicine and cancer: Challenges and opportunities in clinical translation. Int J Pharm. 2021;599:120438.
